GALAPAGOS NV/S (NASDAQ:GLPG) Raised to Strong-Buy at BidaskClub

BidaskClub upgraded shares of GALAPAGOS NV/S (NASDAQ:GLPG) from a buy rating to a strong-buy rating in a research note released on Saturday morning, BidAskClub reports.

Other equities analysts also recently issued reports about the company. Morgan Stanley upped their price target on Thomson Reuters from $66.00 to $67.00 and gave the stock an overweight rating in a research report on Monday, April 29th. HC Wainwright set a $10.00 price target on Jaguar Health and gave the stock a buy rating in a research report on Tuesday, July 2nd. ValuEngine raised XPO Logistics from a strong sell rating to a sell rating in a research report on Thursday, April 4th. Cantor Fitzgerald reaffirmed a buy rating and set a $25.00 price target on shares of Menlo Therapeutics in a research report on Thursday, May 2nd. Finally, Zacks Investment Research downgraded ExlService from a hold rating to a sell rating in a research report on Wednesday, July 10th. Two equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $148.10.

Shares of GLPG stock opened at $170.76 on Friday. The business’s fifty day simple moving average is $127.42. The firm has a market capitalization of $7.47 billion, a P/E ratio of -258.73 and a beta of 1.54. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.31 and a current ratio of 6.31. GALAPAGOS NV/S has a 12-month low of $85.00 and a 12-month high of $174.63.

GALAPAGOS NV/S (NASDAQ:GLPG) last issued its quarterly earnings results on Friday, April 26th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.19) by $0.18. The business had revenue of $46.47 million for the quarter, compared to the consensus estimate of $44.92 million. GALAPAGOS NV/S had a negative return on equity of 3.60% and a negative net margin of 13.24%. As a group, sell-side analysts forecast that GALAPAGOS NV/S will post -4.61 earnings per share for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in the company. FMR LLC grew its holdings in shares of GALAPAGOS NV/S by 35.3% during the first quarter. FMR LLC now owns 502,193 shares of the biotechnology company’s stock valued at $59,148,000 after buying an additional 131,119 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of GALAPAGOS NV/S by 530.8% during the fourth quarter. Bank of New York Mellon Corp now owns 249,137 shares of the biotechnology company’s stock valued at $22,857,000 after buying an additional 209,642 shares during the last quarter. Alps Advisors Inc. grew its holdings in shares of GALAPAGOS NV/S by 14.5% during the first quarter. Alps Advisors Inc. now owns 87,116 shares of the biotechnology company’s stock valued at $10,261,000 after buying an additional 11,045 shares during the last quarter. Millennium Management LLC grew its holdings in shares of GALAPAGOS NV/S by 14.6% during the fourth quarter. Millennium Management LLC now owns 72,538 shares of the biotechnology company’s stock valued at $6,655,000 after buying an additional 9,217 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of GALAPAGOS NV/S during the fourth quarter valued at $6,422,000. 16.32% of the stock is currently owned by hedge funds and other institutional investors.

GALAPAGOS NV/S Company Profile

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.

Featured Story: Using other technical indicators with support levels

Analyst Recommendations for GALAPAGOS NV/S (NASDAQ:GLPG)

Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit